Wedbush Maintains Outperform on Tyra Biosciences, Raises Price Target to $57

Benzinga · 3d ago
Wedbush analyst Robert Driscoll maintains Tyra Biosciences (NASDAQ:TYRA) with a Outperform and raises the price target from $53 to $57.